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Introduction
There is a consensus regarding the need to move beyond 
antibiotic therapy if we want to improve outcomes of 
hospitalized patients with community-acquired pneumonia 
(CAP). However, there is a lack of consensus regarding the use 
of steroids as adjunctive therapy in patients with CAP.  
Eleven meta-analyses have been already published in the 
field of steroids and CAP [1-11]. A primary problem with 
several of these meta-analyses is the inclusion of studies 
with important methodological weaknesses. In addition, in 
a recent meta-analysis which was published in the American 
Journal of Emergency Medicine [10], the authors incorporated 
3 manuscripts which were written in Chinese, making it 
impossible for us to evaluate the quality of those research 
studies. At present, we have more meta-analyses published 
on the topic of steroids and CAP than original randomized 
clinical trials (RCTs), with some of them arriving to different 
conclusions. Meta-analyses are considered the highest level of 
evidence when they are based on high-quality RCTs, but this 
is not the case in the field of steroids and CAP. Because of the 
above, the controversy regarding the use of steroids in patients 
with CAP will continue until further high quality research is 
published. 
With all these caveats in mind, after reviewing recent randomized 
clinical trials [12-19] we consider that there is enough evidence 
to recommend the use of steroids only in a well selected group 
of hospitalized patients with CAP. We also consider that the 
current level of evidence in favor of steroid is weak, and that 
there is a significant possibility that future studies may alter our 
current recommendations. In this editorial, we summarize our 
approach to the use of steroids in hospitalized patients with CAP 
at the University of Louisville Hospital.
Who are the candidates for steroid 
therapy?
Different studies have used different inclusion criteria to 
define a patient as a candidate for steroid therapy. Steroids are 
supposed to improve outcomes by controlling an exaggerated or 
dysregulated host inflammatory response. Hospitalized patients 
with CAP with exaggerated or dysregulated inflammation are 
likely to present with severe CAP with clinical and laboratory 
evidence of sepsis. Translating these concepts into clinical 
practice, we consider patients as candidates for steroid therapy if 
they have clinical or laboratory manifestations compatible with 
early sepsis. Clinically, the patient may have respiratory failure 
requiring ventilator support or the need for high FIO2 (>50%), 
hypotension unresponsive to fluid resuscitation, or evidence of 
newly developed organ dysfunction. Elevated levels of C-reactive 
protein (CRP) have been associated with high cytokine levels 
in patients with CAP [20]. Elevated levels of lactic acid and or 
the presence of metabolic acidosis are associated with sepsis 
and poor outcomes in patients with CAP [21,22]. Based on the 
above, from a laboratory perspective, we consider patients as 
candidates for steroid therapy if they have CRP greater than 
150 mg/L, lactic acid greater than 4 mmol/L, or arterial pH 
is lower than 7.30. There are no clinical or laboratory criteria 
that are diagnostic of sepsis, then the presence of any criteria to 
support diagnosis of sepsis should not be clearly explained by an 
alternative clinical diagnosis. 
In an attempt to limit steroid adverse events, most clinical 
studies excluded patients who are at risk for adverse events. After 
reviewing exclusion criteria from all studies, we recommend 
that patients will not be candidates for steroid therapy if they 
have a recent history of gastrointestinal bleeding, uncontrolled 
diabetes, or if they are severely immunocompromised. 
Retrospective studies reported that the use of steroids in 
patients with influenza pneumonia is associated to worse clinical 
outcomes [23,24]. The presence of influenza as etiology of CAP 
was used as an exclusion criterion in some of the clinical trials 
of steroid use in hospitalized patients with CAP. Production 
of Interferon-gamma (IFN-γ) interferes with replication of 
influenza and other virusues [25]. It can be speculated that 
steroids, by inhibiting IFN-γ, may facilate viral replication in 
patients with influenza CAP or in any other form of viral CAP. 
Until further studies define the role of steroids in patients with 
CAP of viral etiology, we recommend that these patients should 
not be considered candidates for steroid use. If a patient is seen 
in the emergency room with a clinical and laboratory picture 
compatible with CAP and exaggerated inflammatory response, 
we recommend not to wait for microbiological tests to define 
if viral CAP is present. If after initiation of steroid therapy, the 
microbiological workup indicates viral CAP, steroids can be 
discontinued at that point.
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What steroids should be used, and for 
how long?
Investigators have used different types of steroids, different 
doses and different duration of therapy. In an attempt to 
obtain early maximal effect, we consider initially the use of the 
intravenous route, even in patients who are able to take oral 
medications. Our recommendation is to use methylprednisolone 
0.5 mg/kg IV every 12 hours for 5 days. If a patient has a rapid 
improvement, reaches clinical stability, and antibiotic therapy 
is switched from intravenous to oral, we recommended at that 
point to switch from intravenous methylprednisolone to oral 
prednisone 50mg daily to complete the 5 days of therapy.  
A rapid discontinuation of steroid therapy in patients with severe 
CAP may produce a rebound of the inflammatory response. We 
are participating in the current US Department of Veterans 
Affairs trial of steroids in patients with CAP admitted to the ICU, 
the Extended Steroid in CAP (ESCAPe) study (NCT01283009). 
In this study, after initial high dose, steroid dose is tapered in 
an attempt to prevent rebound inflammation. Considering the 
above, we recommend a total of 10 days of steroids. Initial five 
days of high dose steroids with a tapering dose of prednisone for 
the following 5 days with doses of 40mg, 30mg, 20mg, 10mg, 
and 5mg per day. 
When steroid therapy should be 
administered?
In patients with Streptococcus pneumoniae meningitis, the 
use of antibiotic therapy may be followed by an exaggerated 
inflammatory response due to destruction of bacteria and 
the release of intracellular toxins and antigens into tissues. 
Patients with Streptococcus pneumoniae meningitis are 
recommended to be given steroids before or concurrently 
with antibiotic administration [26]. In HIV patients with 
Pneumocystis jirovecci pneumonia (PCP), the killing of the 
organism may produce increased inflammation. In this clinical 
scenario steroids are also recommended concurrently with 
PCP therapy [27]. In a recent publication, we documented that 
patients with CAP in whom macrolides are given before beta-
lactam antibiotics have better clinical outcomes than patients 
treated with macrolides after beta-lactams, suggesting that the 
same phenomenon described in Streptococcus pneumoniae 
meningitis and PCP may be occurring in patients with CAP [28]. 
Our recommendation is to administering steroids concurrently 
with antibiotics or as soon as possible once a patient has 
been identified as a candidate for steroid therapy. The initial 
treatment for severe CAP is commonly implemmented by 
emergency medicine physicians or hospitalists even if patients 
are subsequently admitted to the ICU. It is thus important for 
these clinicians to be updated with the current literature on 
steroids and CAP.
Conclusion
Steroids may improve clinical outcomes in hospitalized patients 
with CAP who have an exaggerated inflammatory response. 
Based on our analysis of the current evidence, the flowchart 
presented in Figure 1 was developed as a guideline for the 
identification of patients who may benefit from steroid use. 
Until further RCTs are published, practitioners should continue 
to use clinical judgment, weight potential benefit and risk, and 
define if the individual patient is a candidate for steroid use.
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Hospitalized Patient with CAP: Candidate for Steroid Therapy
A. At least one of the following: 
1. Respiratory failure with >50% FIO2
2. Hypotension unresponsive to fluids
3. Evidence of new organ dysfunction
B. At least one of the following: 
1. CRP greater than 15 mg/dl 
2. Lactic acid greater than 4 nmol/L
3. Metabolic acidosis with pH < 7.30 
C. No evidence of any of the following:
Recent history of gastrointestinal bleeding
Uncontrolled diabetes
Severe immunocompromised host  
Influenza or other viral etiology of CAP
Plus
Plus
Start methylprednisolone 0.5 mg/kg IV q 12 
hours with first dose given as soon as possible, 
for a total of 5 days.
After 5 days of high dose steroids, followed with 
5 days prednisone tapering dose with 40mg, 
30mg, 20mg, 10mg, and 5mg, per day.
If the patient reaches clinical stability and will 
be switched from IV to oral antibiotics, IV 
steroids can be switched to oral prednisone 





criteria A, plus B, 
plus C
Figure 1 Criteria to define a patient as a candidate for steroid use and suggested course of therapy.
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